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Summary
 
Systemic fungal infections are becoming more common and difficult to treat, yet the pathogen-
esis of these infectious diseases remains poorly understood. In many cases, pathogenicity can be
attributed to the ability of the fungi to adhere to target tissues, but the lack of tractable genetic
systems has limited progress in understanding and interfering with the offending fungal prod-
ucts. In 
 
Blastomyces dermatitidis
 
, the agent of blastomycosis, a respiratory and disseminated my-
cosis of people and animals worldwide, expression of the putative adhesin encoded by the WI-1
gene was investigated as a possible virulence factor. DNA-mediated gene transfer was used to
disrupt the WI-1 locus by allelic replacement, resulting in impaired binding and entry of yeasts
into macrophages, loss of adherence to lung tissue, and abolishment of virulence in mice; each
of these properties was fully restored after reconstitution of WI-1 by means of gene transfer.
These findings establish the pivotal role of WI-1 in adherence and virulence of 
 
B
 
.
 
 dermatitidis
 
yeasts. To our knowledge, they offer the first example of a genetically proven virulence deter-
minant among systemic dimorphic fungi, and underscore the value of reverse genetics for stud-
ies of pathogenesis in these organisms.
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T
 
he systemic dimorphic fungi 
 
Blastomyces dermatitidis
 
,
 
Coccidioides immitis
 
,
 
 Histoplasma capsulatum
 
, 
 
Paracoccidiodes
brasiliensis
 
, and
 
 Sporothrix schenckii
 
 inhabit soil worldwide as
saprophytic molds. They also cause hundreds of thousands
of new fungal respiratory and deep tissue infections annu-
ally in healthy individuals (1, 2) and reactivate as opportu-
nistic infections in up to 40% of AIDS patients in some
geographic regions (1).
Despite the worldwide occurrence and growing inci-
dence of these fungal infections, little is known about the
factors that account for their pathogenicity. In many cases,
pathogenicity can be attributed to the ability of fungi and
other microbes to adhere to target tissues, but the lack of
tractable genetic systems in systemic dimorphic fungi has
severely limited our understanding of the responsible prod-
ucts. This stands in contrast to recent progress that has been
made in genetically manipulating opportunistic fungi such
as 
 
Cryptococcus neoformans
 
 (3) and 
 
Candida albicans
 
 (4), and to
the well-established systems available for manipulating model
fungi such as 
 
Saccharomyces cerevisiae
 
 (5). Nonetheless, there
are theoretical and real advantages to performing genetic
studies of pathogenicity in the pathogenic fungus itself, rather
than in a more genetically manipulable, heterologous fungus.
The systemic dimorphic fungus 
 
Blastomyces dermatitidis
 
 pro-
duces a progressive pulmonary and disseminated infection
and is one of the principal systemic mycoses of humans and
animals worldwide. An immunodominant antigen and puta-
tive adhesin termed WI-1 decorates the fungus (6–8). Cell bi-
ological studies have shown that WI-1 binds the yeast to
CD11b/CD18 and CD14 receptors on human macrophages
(9). Fluorescence staining of the fungal surface and extractions
of cell wall proteins have shown that WI-1 varies in expres-
sion on genetically related strains with reduced virulence (10).
Together, these findings have pointed to a possible role for
WI-1 in the pathogenesis of blastomycosis (11, 12), but for-
mal proof of the role of WI-1 in either adherence or viru-
lence demands additional genetic evidence.
We recently developed the ability to genetically manipu-
late 
 
B
 
.
 
 dermatitidis 
 
(13) using DNA mediated gene transfer.
This transformation system opens the way toward targeting
genes, creating knockout strains, and formally testing the
role of candidate factors such as WI-1 in adherence and
virulence of 
 
B. dermatitidis
 
. Such efforts rest on the feasibil-
ity of accomplishing homologous recombination and gene
disruption at loci encoding putative virulence determinants,
an achievement that has not yet been reported in a systemic 
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dimorphic fungus. Therefore, in this study we sought to
achieve this goal.
We endeavored here to accomplish the following spe-
cific objectives: (a) to target and disrupt the WI-1 locus in
 
B. dermatitidis
 
 by allelic replacement, thus creating WI-1
null strains, and to reconstitute WI-1 expression in knock-
out strains, also by means of gene transfer; (b) to analyze the
adherence-promoting role of WI-1 in binding and phago-
cytosis assays using isogenic strains that do and do not dis-
play the putative WI-1 adhesin; and (c) to quantify the patho-
genicity of these isogenic WI-1 null and reconstituted
strains in an animal model of blastomycosis that closely
mimics the human form of pulmonary disease. We report
here successful homologous gene targeting and allelic re-
placement at the WI-1 locus in 
 
B. dermatitidis
 
, and unam-
biguously establish the pivotal role of WI-1 in both adher-
ence and virulence. To our knowledge, this work illustrates
the first genetically proven virulence factor in 
 
B. dermatitidis
 
and related systemic dimorphic fungi, and emphasizes the
power of reverse genetics for studies of pathogenesis in
these complex microorganisms.
 
Materials and Methods
 
Fungal Strains and Plasmids. Blastomyces dermatitidis 
 
ATCC
strains 26199 and 60915 were used for gene disruption. The
wild-type, parental strain 26199 was isolated originally from a
human patient and is highly virulent in an experimental mouse
model of infection (14). The genetically related strain 60915 was
derived after repeated passage of strain 26199 in vitro and is re-
ported to be 10,000-fold less virulent in mice (15).
The targeting vector pQWhph (see Fig. 1 A) was constructed
as follows: pQE32/WI-1 (8.3 kb) was derived from a Qiagen
 
®
 
expression vector pQE32 (3.5 kb) and an AccIII fragment of the
genomic WI-1 gene (4.8 kb) (8). A BamHI site in the 3
 
9
 
 UTR
of WI-1 was removed by HinDIII digestion and religation. An-
other BamHI site in the 5
 
9
 
 UTR was removed by EcoRI–NruI
deletion. The resulting plasmid, pQW
 
DD
 
, was digested with
BamHI to excise 1.4 kb of WI-1 coding sequence. A 1.4-kb 
 
hph
 
cassette (
 
E. coli hph
 
 driven by 375 bp of WI-1 upstream sequence)
was amplified from pWI-1P (13) using PCR primers TB No. 1
(5
 
9
 
-ATCGGATCCTCGAGGTTTTGGCTTAGGCTC-3
 
9
 
) and
TB No. 2 (5
 
9
 
-ATCGGATCCGGTCGGCATCTACTCTA-3
 
9
 
),
which added BamHI sites (underlined). The 
 
hph
 
 cassette was li-
gated into the pQW
 
DD
 
 BamHI-digested vector, which was then
linearized with HinDIII, and the 1.4-kb HinDIII fragment con-
taining the 3
 
9
 
-untranslated region of WI-1 was ligated back into
place. The orientations of the 
 
hph
 
 cassette and the HinDIII frag-
ment were verified by restriction analysis.
pCB1528, containing the sulfonyl urea resistance gene of 
 
Mag-
neportha grisea
 
, was provided by Drs. James Sweigard (Dupont)
and Paul Szaniszlo (University of Texas, Austin, TX) (16), and
was used for reconstitution of WI-1 in knockout strains.
 
Growth of Fungi. B. dermatitidis
 
 was maintained in the yeast
form by growth on Middlebrook 7H10 agar medium containing
oleic acid–albumin complex (OADC; Sigma Chemical Co.).
Liquid cultures of yeast were grown in 
 
Histoplasma
 
 macrophage
medium (HMM)
 
1
 
 (17) on a rotary shaker at 200 rpm. All cultures
were maintained at 37
 
8
 
C.
To measure the growth rate of yeasts, cells were grown syn-
chronously in HMM and inoculated at a concentration of 2 
 
3
 
10
 
4
 
 per ml into 50 ml of fresh medium. Cultures were incubated
at 37
 
8
 
C on a rotary shaker at 200 rpm for 72 h. Growth rates
were monitored every 24 h by both hemacytometer cell count
and OD
 
600
 
. Doubling time was calculated from the results of
hemacytometer cell counts according to the formula: No. of divi-
sions 
 
5 
 
(Log Nt 
 
2 
 
Log No.)/Log 2, where Log No. is the num-
ber of yeasts at the starting point and Log Nt is the number of
yeasts at each time point analyzed. The doubling time is then
equal to 24 h divided by the number of divisions. Results are the
mean 
 
6
 
 SD of three replicates per time point.
 
Allelic Replacement of WI-1 and Its Reconstitution. B.  dermatiti-
dis
 
 yeast cells of strains 26199 and 60915 were transformed with
5–10 
 
m
 
g of XbaI-linearized pQWhph, using electroporation con-
ditions previously described (13). Transformants were selected on
HMM agar containing 200 
 
m
 
g/ml of hygromycin B. Replicates
plated onto nitrocellulose membranes overlaying brain–heart in-
fusion agar (Difco Labs.) were lysed with 0.2 M NaOH, 0.1% SDS
and 0.5% mercaptoethanol as previously described (18). Mem-
branes were probed with pooled anti–WI-1 mAbs DD5-CB4,
AD3-BD6, BD6-BC4, and CA5-AA3 (19) using standard immu-
noblotting techniques (hybridomas were provided by Drs. Errol
Reiss and Christine Morrison, Centers for Disease Control,
Atlanta, GA).
The multinucleate nature of 
 
B. dermatitidis 
 
yeast had to be ad-
dressed to isolate cells with a WI-1–negative phenotype, as the
presence of heterologous, “silent” nuclei might allow phenotypic
reversion. To obtain genetic homogeneity at the WI-1 locus, each
candidate isolate was taken through several rounds of single-cell
isolation on selective medium with resultant colonies re-screened
as above. This protocol has been shown to render transformants of
multinucleate fungi homogenous for altered genes (20, 21).
Resulting candidates were screened for evidence of gene re-
placement by PCR. Primers internal to the WI-1 gene were used
to determine if candidates contained an intact WI-1 locus. If an in-
tact locus was not detectable, as in candidates 55 and 99 (described
in Results), homologous recombination was assessed by amplifying
the junction between the transformed 
 
hph
 
 gene and sequences 5
 
9
 
to the WI-1 promoter (not on the transforming vector) (see Fig. 1,
A and B). Primers were 5
 
9
 
-TTGTTTGTCTCTGCCCCGTT-
TTC-3
 
9
 
 (forward) and 5
 
9
 
-CGTCGCGGTGAGTTCAGGCTTT-
TTC-3
 
9
 
 (reverse). Knockouts were confirmed by Southern blot
analysis as described below.
To restore the expression of WI-1 in knockout strains, yeast
were cotransformed with pCB1528, together with WI-1 geno-
mic clone 1 (8). After electroporation of 10
 
7
 
 yeasts with a pool of
10 
 
m
 
g of each plasmid, transformants were selected on HMM
plates containing 150 
 
m
 
g/ml of chlorimuron ethyl (Chem Ser-
vice). Out of 19 total transformants, 18 were found to produce
WI-1 in the colony immunoblot assay noted above. Transfor-
mants producing the most WI-1 were passed serially on HMM
under selection as above to obtain a genetically homogeneous
isolate. After repeated passage, strain 4/55 appeared closest to the
parental strain 26199 in WI-1 production and was chosen for fur-
ther study.
 
Detection of WI-1 Protein and DNA in B. dermatitidis.
 
The pres-
ence of WI-1 protein was assayed by immunofluorescence stain-
ing, SDS-PAGE, and Western blotting. Immunofluorescence
staining was performed as previously described (8–10). In brief,
yeast (10
 
6
 
 cells) were stained for WI-1 indirectly using 1 
 
m
 
g anti–
WI-1 mAb DD5-CB4 followed by goat anti–mouse IgG-FITC.
Stained cells were inspected for fluorescence microscopically us-
 
1
 
Abbreviation used in this paper:
 
 HMM, 
 
Histoplasma
 
 macrophage medium. 
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ing an Olympus BX60 fluorescent microscope or a FACScan
 
®
 
flow cytometer (Becton Dickinson). Cell-associated proteins were
extracted by boiling yeast in treatment buffer containing 1.5%
SDS, and 5.0% 2-ME for 3–5 min, followed by analysis of the
cell-free material by SDS-PAGE and Western blotting using
anti–WI-1 mAb DD5-CB4 as previously described (8). For
Southern blot analysis, chromosomal DNA was prepared by
grinding cells in liquid nitrogen and extracting them in detergent
as previously described (13). Purified DNA was restricted with
XbaI (Promega Corp.) at a ratio of 40 U/10 
 
m
 
g of DNA, incu-
bated at 37
 
8
 
C overnight, and then separated on 1% agarose gel
and transferred to nitrocellulose membrane. A 100-ng aliquot of
probe was labeled with 
 
a
 
-[
 
32
 
P]dCTP to a specific activity of 10
 
9
 
cpm/
 
m
 
g using random oligonucleotides as primers (Amersham
Pharmacia Biotech). Washed Southern blots were used to expose
Kodak XAR-5 film with intensifying screens at 
 
2
 
80
 
8
 
C.
 
Binding and Phagocytosis Assays.
 
Murine macrophage cell line
J774.16 (22–25), provided by Dr. Arturo Casadevall (Yeshiva
University, NY), was used in most in vitro binding and phagocy-
tosis assays. Further experiments were done with resident perito-
neal macrophages of BALB/c mice. Macrophages were grown in
DMEM (GIBCO BRL) with 10% heat-inactivated fetal calf se-
rum (HyClone Laboratories Inc.), 10% NCTC-109 medium, and
1% nonessential amino acids (GIBCO BRL), and plated at 2.5 
 
3
 
10
 
4
 
 cells per well in 16-well tissue culture Chamber Slides (Nunc
Inc.). Cells were stimulated with 500 U/ml of recombinant mu-
rine IFN-
 
g
 
 (Boehringer Mannheim). After overnight incubation
at 37
 
8
 
C/8% CO
 
2
 
, medium in each well was replaced with fresh
medium containing 500 U of IFN-
 
g
 
/ml, 3 
 
m
 
g/ml of LPS (Sigma
Chemical Co.) and 
 
B. dermatitidis
 
 yeasts.
Binding and phagocytosis of yeasts was analyzed in vitro as
previously described (22–25). In brief, yeasts were heat-killed for
45 min at 65
 
8
 
C and stained with rhodamine isothiocyanate
(RITC) (10 
 
m
 
g/ml). Assays done in the presence and absence of
complement used 10% normal mouse serum (NMS) and heat-
inactivated NMS, respectively. Complement was inactivated by
heating NMS at 56
 
8
 
C for 30 min. Yeasts and macrophages were
incubated at an E/T ratio of 1:4 for varying periods at 37
 
8
 
C/8%
CO
 
2
 
. Unattached yeasts were removed by washing wells three
times with PBS. Attached but uningested yeasts were stained
with 0.1% Uvitex 2B (Specialty Chemicals for Medical Diagnos-
tics, Germany) for 30 s. Cells were fixed in 1% paraformaldehyde
for 15 min. After fixation, glycerol was added to the slide. To
quantify binding and phagocytosis, the number of yeasts attached
to and ingested by 100 macrophages was counted at 
 
3
 
1,000 us-
ing a U-MWU fluorescence cube in an Olympus BX60 micro-
scope (Leeds Precision Instruments, Inc.). The association index
is defined as the number of attached and ingested yeasts divided
by the number of macrophages counted. The ingestion index is
defined as the number of yeasts ingested per macrophage. Results
are expressed as the mean 
 
6
 
 SEM of at least three experiments.
Binding of yeast to lung tissue was analyzed using modifica-
tions to an ex vivo assay described previously (26). Lung tissue
from a healthy mouse was embedded in O.C.T. compound
(Miles Inc.), frozen in liquid isopentane at 
 
2
 
80
 
8
 
C, and sliced into
thin, 6-
 
m
 
m sections in a cryostat at 
 
2
 
20
 
8
 
C. Sections were applied
to Superfast/plus
 
®
 
-coated glass slides (Fisherbrand; Fisher Scien-
tific Co.) and air dried. RITC-stained yeasts (10
 
6
 
) in 0.1 ml
HBSS containing 20 mM Hepes, 0.25% BSA, and 3 mM CaCl
 
2
 
,
were added to a wax-inscribed circle of the tissue section. Slides
were incubated for 60 min at 37
 
8
 
C, washed three times with
HBSS to remove unattached yeasts, and fixed with 1.25% glu-
taraldehyde for 35 min at room temperature. Binding of yeasts
 
was enumerated by counting the number that adhered to a 0.01
mm
 
2
 
 area of the slide viewed at 
 
3
 
600 using an Olympus IX50
fluorescent microscope (Leeds Precision Instruments). Results are
expressed as the mean 
 
6
 
 SEM of at least six experiments.
 
Experimental Model of B. dermatitidis Infection.
 
Male BALB/c
mice 
 
z
 
5–6 wk of age (Harlan Sprague Dawley) were infected in-
tranasally with 
 
B. dermatitidis 
 
yeasts as previously described (27).
In brief, mice were anesthetized with inhaled Metafane® (Mal-
linckrodt Veterinary Inc.) to administer a 25-ml suspension of
yeast cells dropwise into their nares. The minimum number of
yeasts needed to achieve a lethal infection was established in pre-
liminary work as 102 intranasally for ATCC 26199, and 106 for
ATCC 60915. Mice were housed according to guidelines of the
University of Wisconsin Animal Care Committee, which approved
this work.
Statistical Analysis. Kaplan Meier (28) survival curves were
generated for mice that received a lethal infection. Survival times
of mice that were alive by the end of the study were regarded as
censored. Time data were analyzed by the log rank statistic and
exact P values were computed using the statistical package Stat
Xact-3 by CYTEL Software Corporation. The survival of two
groups are considered to be significantly different if the two-sided
P value is ,0.05. When multiple comparisons were made simul-
taneously, P values were adjusted according to Bonferroni’s cor-
rection to protect the overall significance level of 0.05.
Differences between B. dermatitidis strains in the number of
CFU in tissue were analyzed statistically using the Wilcoxon
Rank test for nonparametric data (28). Differences between
strains in binding and phagocytosis were analyzed using methods
for standard analysis of variance (29). P , 0.05 was considered
significant. 
Results
Allelic Replacement of WI-1 and Its Reconstitution. Our gene
targeting efforts capitalized on the preferred fate of incom-
ing DNA in B. dermatitidis, which is integrative transforma-
tion (13). Substantial WI-1 DNA flanking the hph selectable
marker was used to target the knockout vector pQWhph
and achieve the desired crossover event (Fig. 1 A).
WI-1 was disrupted by allelic replacement in ATCC
strains 26199 and 60915. Presumptive evidence of homolo-
gous recombination was sought by PCR amplification of the
junction between the hph gene on the transforming vector
and the upstream sequences 59 to the WI-1 promoter (not
on the transforming vector) (Fig. 1, A and B). Either of
two possible products could signal such an event. A joint
fragment of 1.6 kb would be amplified if chromosomal
DNA had recombined at the 1 kb of WI-1 flanking se-
quence on pQWhph, whereas a joint fragment of 675 bp
would be amplified if chromosomal DNA had recombined
within the WI-1 minipromoter (375 bp) that directs ex-
pression of the hph gene. In each positive candidate (strains
55 and 99) the amplified joint fragment was 675 bp (Fig.
1 B). To verify the amplified product’s authenticity, it was
digested with EcoRV and AatII (Fig. 1 B); the resulting
DNA fragments corresponded in size to predictions based
on the genomic sequence of WI-1 (8). Southern blot anal-
yses described below confirmed the initial PCR results and
demonstrated allelic replacement of WI-1 after screening1210 A Virulence Determinant of B. dermatitidis
60 transformants of ATCC 26199 and 100 transformants of
ATCC 60915. The frequency of homologous targeting at
the WI-1 locus was 1–2%.
WI-1 expression was restored in one of the knockout
strains, 55, by means of gene transfer involving cotransforma-
tion with pCB1528 and genomic clone 1 containing WI-1
(as described in Materials and Methods), yielding strain 4/55.
Phenotypic and Genotypic Analyses of Recombinant Strains.
The phenotype and genotype of the knockouts and the re-
constituted strain were established by anti–WI-1 mAb fluo-
rescence staining, Western blots of extracted protein, and
Southern blot analysis (Fig. 2, A–C). Surface WI-1 was not
detectable on knockout strain 55 by either FACS® analysis
or Western blotting of extracted cell wall proteins (Fig. 2,
A and B). In contrast, the amount of surface WI-1 on the
reconstituted strain 4/55 was comparable to, if not greater
than, the amount detected on the parental strain. Similar
results were observed in isogenic strains ATCC 60915 and
knockout strain 99 (data not shown).
To confirm that WI-1 had been disrupted by allelic replace-
ment, and to analyze the nature of the transforming event,
Southern blot analyses were performed (Fig. 2 C). The up-
stream WI-1 probe hybridized to a 9.3-kb XbaI fragment
in DNA from parental strains 26199 and 60915, but not
knockout strains 55 and 99. Instead, the WI-1 probe hy-
bridized to a novel fragment of z8.3 kb in each of these
knockout strains. The hph gene probe also hybridized with
this same 8.3-kb fragment in the knockouts, indicating that
the residual, upstream sequence for WI-1 and the hph se-
quence were on the same DNA fragment. For each knock-
out strain, the presence of a single band hybridizing with
the WI-1 probe, which differs in size from the respective
one in the parental strain, indicates a disrupted WI-1 locus
without other ectopic integrations. The size of this fragment
in knockout strains (z8.3 kb; Fig. 2 C), together with the
size of the joint fragment amplified in PCR (675 bp; Fig.
1 B), suggests that transforming DNA crossed over at the
375-bp stretch of homology (minipromoter) with the 59
region of WI-1, excising z1 kb of coding sequence. This
event probably placed the full 59 region and the complete,
endogenous WI-1 promoter upstream of E. coli hph (Fig.
1 B), perhaps transcribing hph more efficiently.
Southern blot analysis of reconstituted strain 4/55 dem-
onstrated that the WI-1 transgene was located on a single
XbaI fragment that differed in size from the retained 8.3-kb
fragment harboring an hph-disrupted copy of WI-1 (Fig.
2 C). This indicated that the WI-1 transgene had integrated
ectopically, rather than homologously, into the chromo-
some in a single copy.
Thus, phenotypic and genotypic analyses demonstrated
that isogenic strains differing in the expression of WI-1 had
been created: wild-type parental strain 26199, with a high
Figure 1. (A) Strategy for tar-
geting and replacing the WI-1
locus in B. dermatitidis. Antic-
ipated homologous crossover
leading to a gene replacement
event at the WI-1 locus. Linear-
ized pQWhph can direct the hph
gene to the WI-1 locus through
homologous crossover in two
ways.  3’s depict crossing over at
1 kb of WI-1 59 flanking se-
quence (all WI-1 coding, desig-
nated in black) and at 2.5 kb of
WI-1 39 flanking sequence (881
bp of WI-1 coding in black and
1395 bp of noncoding in hori-
zontal lines). Alternatively, the
broken line depicts crossing over
at a short region of the 375-bp
WI-1 minipromoter in front of
the hph gene. Either crossover
event would replace most of the
WI-1 coding region with the
hph cassette. (B) PCR analysis for
targeted gene replacement of
WI-1. Candidates isolated in
colony screening for a WI-1 null
phenotype as described (Materi-
als and Methods) were further
analyzed for targeted recombina-
tion by PCR amplification of a
novel junction fragment span-
ning the WI-1 59 region (not present on the targeting vector) and the hph gene. The forward primer (59-TTGTTTGTCTCTGCCCCGTTTTC-39 at
2644 in the WI-1 59 region) is present only in the endogenous locus, whereas the reverse primer (59-CGTCGCGGTGAGTTCAGGCTTTTTC-39 at
131) is present in the hph gene on transforming DNA. The resulting 675-bp fragment is amplified if WI-1 sequences have been interrupted by hph in the
manner depicted by a dashed line in A, yielding an interrupted locus shown at the bottom of A and in B. The product’s authenticity is confirmed by the
presence of EcoRV and AatII restriction sites in the WI-1 upstream segment of the product, as shown in an accompanying agarose gel, and in accord
with published WI-1 genomic sequence (8).1211 Brandhorst et al.
level of expression; strain 55, devoid of WI-1; and strain
4/55, with expression restored to the level of wild-type, or
perhaps higher. In addition, parental strain 60915 contain-
ing WI-1 and its isogenic knockout strain (99) lacking WI-1
were also developed (Fig. 2 C).
Defective Binding and Entry of WI-1 Knockout Yeast. Be-
cause WI-1 is believed to bind yeasts to macrophages (8–10),
we investigated whether WI-1 knockout yeasts were capa-
ble of binding. Knockout yeasts bound and entered murine
macrophages poorly (Fig. 3 A). The number of knockout
yeasts bound to or inside of macrophages in vitro was far
lower than that for wild-type yeasts at all time points be-
tween 15 min and 6 h of incubation. At 6 h, the association
index for the knockout yeast was one-sixth the value for
the wild-type yeast, and the ingestion index was one-
eighth as high. These yeast strains bound resident mouse
peritoneal macrophages in a manner similar to that observed
for the macrophage cell line J774.16 (data not shown). The
defect in binding and entering macrophages was restored
fully in the knockout when 10% serum was added as a
source of complement (Fig. 3 B) or after WI-1 was reex-
pressed in strain 4/55 (Fig. 3 C). These findings imply that
WI-1 mediates binding and entry of yeast into macro-
phages in the opsonin-poor environment of the lung early
in the course of infection, before tissues are inflamed and
serum exudes into the alveolus.
To determine whether knockout yeasts bound poorly
within the noninflamed lung itself, we quantified the num-
ber of yeasts that adhered to thin sections of lung in an ex
vivo binding assay. Again, the knockout bound poorly,
whereas both the wild-type isolate and the WI-1 reconsti-
tuted isolate 4/55 bound avidly (Fig. 3 D), emphasizing the
key role of WI-1 in promoting interactions directly with
constituents of the lung alveolus.
Indispensable Role of WI-1 in Virulence. We hypothesized
that yeasts unable to bind lung tissues and enter macrophages
during infection would be much less virulent, and tested this
in a previously described murine model of lethal pulmonary
blastomycosis (27). All mice infected with the wild-type
strain ATCC 26199 at a dose of 102 yeasts died from an over-
whelming pulmonary and disseminated infection several
weeks after inoculation, whereas all mice infected with the
same dose of isogenic, WI-1 knockout strain 55 lived and ap-
peared healthy during observation over 72 d (Fig. 4 A). Mice
infected with either 103 or 104 yeasts of knockout strain 55,
which are respectively 10 and 100 times the lethal dose of
wild-type yeast, also survived and appeared healthy during
the 72-d observation period. Finally, lethality studies compar-
ing parental strain ATCC 60915 (15) and its isogenic WI-1
knockout strain 99 yielded similar results (data not shown).
Representative mice infected with knockout strain 55
were killed 3 wk after they were infected with 103 yeasts.
They had ,600 organisms in the lungs and none in the
liver or spleen, suggesting that strain 55 produces a self-lim-
ited infection. To analyze the evolution and clearance of
infection with the knockout and wild-type strains over
time, groups of mice were tested serially for the burden of
infection 1–14 d after they were infected intranasally with
104 yeasts. The number of yeasts in the lungs of mice in-
fected with the knockout remained low throughout the
study interval, whereas the number for the wild-type strain
26199 grew steadily; a sharp difference in the burden of in-
fection between the strains was evident by 3 d and became
statistically significant after 1 wk of infection (Table I). On
Figure 2. Phenotype and genotype of WI-1 knockout strains and reconstituted strains. Flow
cytometry (A) and Western blot analyses (B) were done using anti–WI-1 mAb DD5CB4 (8–10,
19). A and B show results for wild-type parental strain ATCC 26199, isogenic knockout strain
55, and WI-1 reconstituted strain 4/55; another parental strain, ATCC 60915, and its isogenic
WI-1 knockout strain, 99, gave similar results that are not shown. (A) FACS® analysis of WI-1
surface expression. WI-1 was stained with 1–2 mg of purified mAb per 106 yeasts. Nonspecific
mAb binding was assessed with IgG2A isotype control mAb used at the same concentration as
anti–WI-1 mAb. Values for the mean channel fluorescence intensity of anti–WI-1 binding were:
wild-type strain 26199 5 318; WI-1 reconstituted strain 4/55 5 403; and WI-1 knockout strain
55 5 5. (B) Western blot analysis of WI-1 in yeast cell extracts. Yeast cell proteins were extracted
as described in Materials and Methods, using 107 yeasts per strain, and loading an equivalent vol-
ume of cell-free extract per lane. Lane 1 is a positive control with 4 mg of purified WI-1. (C) Southern blot analysis of WI-1 targeting and replacement.
Genomic DNAs were restricted with XbaI. Strains are wild-type parent strain ATCC 26199, isogenic knockout strain 55, and WI-1 reconstituted strain
4/55. ATCC 60915 and isogenic WI-1 knockout strain 99 are included to illustrate targeted gene replacement of WI-1 in a second strain of B. dermatiti-
dis. The hph probe contains only hph coding sequence. The WI-1 probe is an AatII/EcoRI fragment from an upstream region of the gene (nucleotides
21091 to 2388), which is not carried on the knockout vector QWhph.1212 A Virulence Determinant of B. dermatitidis
postmortem examination, the lungs of mice infected with
the knockout were macroscopically normal, but contained
a small number of well-formed granulomas with seques-
tered organisms (Fig. 4 B). The lungs of mice infected with
the wild-type strain were filled with organisms and wide-
spread inflammation. Taken together, these findings sug-
gest that eliminating WI-1 expression greatly reduces the
pathogenicity of the yeast.
Figure 3. WI-1 mediated
binding of B. dermatitidis to mac-
rophages and lung tissue. (A)
Binding and entry of macro-
phages by B. dermatitidis wild-
type and knockout yeast. The
upper portion of the panel shows
binding of yeasts to macrophage
J774.16 cells. The lower portion
shows entry of yeasts into the
macrophages. Binding and entry
were quantified after incubation
for varying intervals as shown.
Unopsonized yeasts were added
to wells of chamber slides con-
taining 2.5 3 104 macrophages at
a ratio of four yeast cells per
macrophage. The association in-
dex is defined as the number of
attached and ingested yeasts per
macrophage. The ingestion in-
dex is defined as the number of
yeasts internalized per macro-
phage. Results are mean 6 SEM
of three independent experi-
ments. The two strains differ sig-
nificantly in binding and entry of
macrophages for all time points
after 1 h of incubation (P  ,
0.01). (B) Complement reverses
defects in binding and entry in
the WI-1 knockout strain. Assays
were done as in A, except that
they included 10% fresh mouse
serum (as a source of comple-
ment) or heat-inactivated mouse
serum (as a control). Results are
the mean 6 SEM for three sepa-
rate experiments. Wild-type and
knockout yeast differ signifi-
cantly from each other in bind-
ing and ingestion both in the
absence of serum and in the
presence of heat-inactivated se-
rum (P , 0.001 for each com-
parison), but not in the presence
of fresh serum. (C) Defective
binding and entry of macro-
phages by WI-1 knockout yeasts
is reversed after reexpression of
WI-1. Unopsonized yeasts were
incubated with macrophages for
6 h; results are the mean 6 SEM
of three separate experiments.
Wild-type yeasts and WI-1 re-
constituted yeasts bind and enter
macrophages significantly better
than do knockout yeasts (P  ,
0.001 for each comparison). (D)
Binding of yeasts to lung tissue
ex vivo. Lungs of normal mice
were removed and cryopre-
served and 6-mm sections were applied to glass slides as in Materials and Methods. The number of unopsonized yeasts attached to lung tissue sections was
quantified. The extent of binding is defined as the number of yeasts attached per 0.01 mm2 of lung tissue, which was determined by inspecting a high
power field at 3600 and counting 30 fields per strain in each experiment. Results are the mean 6 SEM of six independent experiments. Wild-type yeasts
and WI-1 reconstituted yeasts bind to lung tissue significantly better than do knockout yeasts (P , 0.001 for each comparison).1213 Brandhorst et al.
We found no evidence for a growth defect in strain 55
knockout yeasts, as an alternative explanation for its re-
duced pathogenicity. Doubling times in liquid culture were
calculated to be 17.5 h for the knockout strain and 17.1 h
for the wild-type strain at 48 h after inoculation into liquid,
which represented the peak log phase of growth. Wild-
type parental yeasts and strain 55 knockout yeast appeared
morphologically similar on agar and on microscopic exam-
ination. However, knocking out WI-1 in strain 99 led to
excessive elongation into pseudohyphae, with few round
yeast cells like those seen in parental ATCC strain 60915
(data not shown). This could be due to accumulated defects
in the cell wall, as parental strain 60915 also has diminished
a-(1,3)-glucan (30).
Restoration of Virulence in the Knockout Strain. We next
confirmed that loss of WI-1 is directly responsible for re-
duced virulence of strain 55 in vivo, by showing that re-
stored expression of WI-1 conferred pathogenicity. The
WI-1 reconstituted strain 4/55 killed 100% of infected
mice, as did the wild-type strain 26199 (Fig. 4 C). Strain
Figure 4. Targeted gene replacement of WI-1 reduces the pathogenicity of B. dermatitidis. (A) Survival after infection with wild-type strain 26199 and
WI-1 knockout strain 55. Male BALB/c mice (n 5 15 mice/group) were infected intranasally with yeast cells of each strain, in varied doses. Survival was
monitored for 72 d after infection. The two groups differ significantly (P , 0.001) at each infectious dose tested. The experiment shown is representative
of three independent experiments. The phenotype of knockout yeasts was stable; no revertants were identified among yeasts grown from mice infected
with strain 55. (B) Gross and microscopic pathology of mice infected with ATCC 26199 wild-type yeasts or WI-1 knockout yeasts. Mice were analyzed
3 wk after infection. Lungs were stained with hematoxylin and eosin to assess inflammation, and with Gomori methenamine silver to visualize yeasts. The
arrow denotes an isolated granuloma surrounded by normal lung tissue in a mouse infected with the WI-1 knockout strain 55. (C) Survival after infection
with wild-type strain 26199, WI-1 knockout strain 55, and WI-1 reconstituted strain 4/55. Survival experiments were done as in A, using a dose of 104
yeasts to establish infection. The wild-type and WI-1 reconstituted strains were significantly different from the WI-1 knockout strain (P , 0.001 for each
comparison).1214 A Virulence Determinant of B. dermatitidis
4/55 accelerated the time to death and thus appeared more
virulent than the parental strain 26199. Strain 4/55 yeast
also displayed larger amounts of WI-1 than did the parent
strain, as observed in FACS® and in Western blots of yeast
cell extracts (Fig. 2, A and B), suggesting a possible dose
effect on virulence. To assess the appearance and extent of
infection with strain 4/55, mice were analyzed at the time
of death. These mice demonstrated severe pulmonary and
disseminated disease with .107 yeasts in the lungs and
.2.5 3 104 yeasts in the liver, indicating that they died
from an overwhelming infection, similar to that observed
with wild-type yeast.
Discussion
Formal proof of the importance of a virulence determi-
nant requires fulfillment of a “molecular” Koch’s postulate:
loss of virulence upon gene disruption, and restoration of
virulence upon gene reconstitution (31). Prior studies of
systemic dimorphic fungi have implicated candidate viru-
lence factors through correlative and other means (32), but
none of the observations have been substantiated by ge-
netic tests, leaving their validity open to debate. Past studies
that have implicated WI-1 in adherence, pathogenesis, and
virulence are one such example, using exclusively non-
genetic methods. Genetic intractability of B. dermatitidis and
related fungi has, until very recently, prevented definitive
studies. In addition to the transformation system recently de-
scribed for B. dermatitidis (13), high efficiency transformation
can be accomplished in the dimorphic fungus H. capsulatum
(33), and the molecular and genetic tools for manipulation of
that pathogen are now in hand (33–35).
In this study, we analyzed the pathogenetic role of WI-1
in B. dermatitidis by reverse genetics, overcoming past limi-
tations in virulence studies of systemic dimorphic fungi.
Here, the WI-1 locus was targeted and disrupted by allelic
replacement using the dominant selectable marker encod-
ing resistance to hygromycin B. Evidence of homologous
gene targeting and elimination of WI-1 expression was
provided at both the DNA and protein levels. The fre-
quency of homologous gene targeting at the WI-1 locus
ranged from 1 to 2% in the two independent strains stud-
ied, 26199 and 60915, which compares favorably with rates
observed in a study of H. capsulatum. Woods et al. (35) re-
ported that homologous gene targeting is a rare event in
that pathogen, occurring at a frequency of ,1023 at the
URA5 locus. Several reasons could account for the higher
frequency of targeting in the current study of B. dermatitidis,
including the differences in pathogen, genetic locus, and
gene targeting strategy.
We suspect that the gene targeting strategy used here
was a critical feature and increased the rate of homologous
recombination. Our targeting plasmid allowed a crossover
event to occur in either of two locations in the 59 region, as
illustrated in Fig. 1 A: a long, 1-kb stretch of WI-1 coding
sequence, or a shorter 375-nucleotide stretch of WI-1
minipromoter that served to express E. coli hph in trans-
forming DNA. The plasmid had been designed so that the
long stretch of homologous sequence in the 59 (and 39) re-
gion might enhance the frequency of gene targeting. Sur-
prisingly, B. dermatitidis handled the transforming DNA in
an unanticipated way in both instances in which homolo-
gous recombination was observed. Crossing over in the 59
region occurred preferentially at the shorter stretch of ho-
mologous sequence rather than at the longer stretch. Evi-
dence for the nature of the crossover event includes the size
of the joint fragment PCR-amplified from the knockout
strains (Fig. 1 B), and the size of the hybridizing band de-
tected in Southern blot analysis (Fig. 2 C). This type of
crossover event may have had the effect of “trapping” a
more active WI-1 promoter in front of the hph coding se-
quence. Gene targeting by “promoter trapping” has been
described in mammalian embryonic stem cells (36), where
the expression of selection genes was made dependent on
acquisition of transcriptional start signals from host DNA,
thereby enriching for homologous recombination among
preponderantly random integrations. This sort of targeting
strategy may have broader application to other genes and
dimorphic fungi if it renders them more amenable to allelic
replacement and gene disruption by enhancing low fre-
quencies of homologous recombination.
The isogenic strain pairs created here were used to inves-
tigate the role of WI-1 in the pathogenesis of blastomyco-
sis. Prior work using cell biological approaches suggested
that WI-1 promotes binding to human macrophages (8–10).
Genetically related strains of B. dermatitidis that vary in sur-
face expression of WI-1 showed concordant differences in
binding to macrophages in vitro: Fab fragments of anti–
Table I. Burden of Yeast in Lungs after Mice Were Infected with B. dermatitidis*
Strain
Time of death
3 h 24 h 3 d 7 d‡ 14 d§
Knockout strain 55 750 6 150 850 6 150 750 6 250 500 6 100 1,250 6 300
ATCC 26199 600 6 150 500 6 150 2,300 6 750 4,600 6 1,350 60,450 6 15,550
*Mean CFU/lung 6 SEM, n 5 6 mice per time point for each yeast strain.
‡P 5 0.06 when comparing the burden of infection between the strains at this time point.
§P 5 0.005 when comparing the burden of infection between the strains at this time point.1215 Brandhorst et al.
WI-1 mAbs blocked a portion of binding by yeast to mac-
rophages, and purified WI-1 on polystyrene microspheres
greatly enhanced their binding to the macrophages. Taken
together, these findings suggested an adhesive property of
WI-1. They could not address whether WI-1 is necessary
or simply sufficient for binding yeast to cells, and to what
extent binding by yeast would be impaired or eliminated in
the absence of WI-1. Our study confirms and extends prior
observations by demonstrating that WI-1 is necessary for
binding the yeast to macrophages in vitro, as well to lung
tissue ex vivo. Wild-type yeast bound avidly, in a time-
dependent manner, whereas knockout yeast were impaired
profoundly in their binding, and binding was largely re-
stored in the WI-1 reconstituted strain. In addition, cells
that bound poorly did not enter macrophages, as evidenced
by low ingestion indices during the course of the incuba-
tion. In addition to data generated with the J774 macro-
phage-like cell line and lung tissue sections, similar trends
were observed with peritoneal macrophages from mice.
These observations suggest that WI-1 serves as the principal
ligand mediating attachment of yeast to macrophages and
host tissue, and that other ligands play a lesser role.
The isogenic strains also were used to address the role of
WI-1 in virulence. In a prior study (10), altered WI-1 ex-
pression in genetically related wild-type and variant strains
correlated with differences in virulence. Variant strains
with the lowest reported virulence surprisingly had the
highest level of surface WI-1 (and binding to macrophages).
Thus, a possible interpretation of that study could be that
WI-1 interferes with virulence of the yeast. However,
those variants also had multiple coexisting defects, includ-
ing impaired secretion of WI-1 and reduced or absent
surface expression of the polymer a-(1,3)-glucan. The
multiple defects impeded a definite conclusion about an in-
dependent role of WI-1 or any other single component,
and underscored the need for reverse genetics to allow a
definitive conclusion.
This study tackles this issue and demonstrates firmly that
WI-1 is indispensable for the pathogenicity of B. dermatiti-
dis. Knocking out WI-1 in wild-type strain 26199 rendered
these yeast unable to establish a lethal pulmonary infection,
even when administered at 100 times the minimal lethal in-
oculum. Similar results were observed after knocking out
WI-1 in a second strain, 60915, further strengthening our
conclusions about the importance of WI-1. Analyses of or-
gan load and distribution of infection showed that wild-
type yeast grew steadily in the lung and increased sharply in
number by 7–14 d after infection. Although the number of
knockout yeast that entered the lung was comparable to
that of the wild-type immediately after infection, the num-
ber of knockout yeast in the lung remained low through-
out the observation period. The persistently low number
was probably not due to a growth defect, since knockout
and wild-type yeast demonstrated a similar doubling time
in vitro. After primary lung infection, wild-type yeast also
disseminated to liver and spleen, whereas knockout yeast
did not disseminate. This could reflect the ability of wild-
type yeast to enter macrophages and disseminate while in-
side them, or possibly a burden of yeast beyond the lung’s
capacity. On histological examination, the pulmonary alve-
oli of mice infected with the wild-type were obliterated
with inflammation and yeast, whereas the lungs of mice
that received the knockout appeared mostly normal, except
for focal well-formed granulomas with small numbers of
sequestered organisms. These findings suggest that cell-
mediated immunity remained intact and facilitated clearance
of knockout yeasts. If this is true, administration of WI-1
knockout yeasts might vaccinate against B. dermatitidis in-
fection due to wild-type yeasts.
The indispensable role of WI-1 in pathogenicity is sub-
stantiated by this study, but the mechanism(s) whereby the
molecule exerts its effect requires more investigation. A deeper
understanding of WI-1 and other fungal virulence mecha-
nisms will be important in developing new pharmacologi-
cal and immunological approaches to management of sys-
temic fungal infections. Moreover, insight into where and
when fungal virulence determinants are expressed in vivo
and how virulence genes are regulated should provide new
information about how pathogenic fungi sense the inimical
environment of the host and adapt to it successfully. Our
study marks a significant first advance toward these goals by
establishing WI-1 as a key virulence determinant of B. derma-
titidis worthy of further investigation.
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